About this medicine

Galantamine is a cholinesterase inhibitor for Alzheimer's dementia symptoms. The UK records distinguish once-daily prolonged-release capsules from twice-daily oral solution. A change of formulation therefore needs an explicit schedule, even when the intended total daily milligrams are unchanged.

What is this medicine used for?

The checked licence covers mild to moderately severe Alzheimer's dementia, not ordinary forgetfulness or every dementia subtype. NICE discusses galantamine for dementia with Lewy bodies only when donepezil and rivastigmine are not tolerated; that is separate from the checked licensed indication.

Which warning signs need help?

Stop galantamine and obtain advice at the first skin rash; blistering, a spreading rash, collapse, seizure or severe allergy requires urgent assessment. Suspected overdose also needs prompt help because excessive cholinergic effects can disturb breathing and heart rhythm. Use emergency services appropriate to the country you are actually in.

Trials in mild cognitive impairment did not show benefit and found more deaths with galantamine than placebo. This population is distinct from Alzheimer's dementia; the finding must not be turned into either a claim of prevention or a simple causal explanation for all deaths.

How do I take it safely?

Gatalin XL starts at 8 mg once daily for four weeks, then 16 mg; 24 mg is considered only after another adequate assessment period. The solution instead starts at 4 mg twice daily, progressing through 8 and potentially 12 mg twice daily at intervals of at least four weeks.

What side effects should I know about?

Dizziness, headache, tiredness, fainting, nausea, vomiting, reduced appetite and weight loss are recognised. Report persistent poor intake, falls, hallucinations or a noticeably slow pulse. Side effects can reflect the medicine, another illness or both; treatment needs review rather than an automatic dose increase.

Who needs extra care with this medicine?

The checked UK products are contraindicated in severe liver impairment, creatinine clearance below 9 ml/min, or combined significant kidney and liver dysfunction. Their renal instructions differ from US labels. Moderate liver impairment requires slower initiation and a 16 mg/day ceiling; formulation-specific instructions matter.

Can it affect my other medicines?

Do not combine cholinesterase inhibitors without specialist justification. CYP2D6 or CYP3A4 inhibitors, including certain antidepressants, antibiotics and antifungals, may increase exposure. Pulse-slowing drugs and medicines affecting cardiac repolarisation require review. Tell the anaesthetic team about galantamine.

What check-ups will I need?

SPS recommends baseline pulse, weight, electrolytes, liver tests and renal function for galantamine, with ECG consideration where indicated. Pulse checks are monthly during initiation or adjustment and six-monthly when stable; monitor weight and treatment benefit as well.

What about pregnancy, breastfeeding and age?

There is no relevant paediatric dementia use. Pregnancy requires caution because human evidence is limited, and the patient leaflet advises against breastfeeding during treatment. Older age does not remove the need to assess kidney function, body weight, concurrent medicines and the ability to take treatment consistently.

What if I miss a dose or want to stop?

Swallow prolonged-release capsules whole, preferably with morning food; do not chew or crush them. If one dose is forgotten, skip it. If more than one has been missed, contact the clinician before restarting. Never double the next dose or take both formulations as an accidental duplicate.

How does it work?

Galantamine slows the breakdown of acetylcholine, a chemical messenger used by brain cells. It reduces the activity of acetylcholinesterase, an enzyme, or protein that helps break acetylcholine down after a message has been sent. More of the messenger can then remain available between cells.

This supports remaining cholinergic activity, meaning communication that uses acetylcholine, rather than replacing nerve cells that have been lost. The aim is to help with symptoms, and there is no evidence that the medicine stops the underlying disease process. Benefit is assessed through memory, thinking and daily activities, alongside how well the person tolerates treatment.

How does it affect my body?

Cholinergic effects can alter digestion and pulse. Nausea and vomiting often appear during initiation or dose increases, and reduced appetite may lead to weight loss. Adequate fluid intake and attention to everyday functioning matter alongside any change in memory symptoms.

How does my body process it?

CYP2D6 and CYP3A4 contribute to metabolism. Oral solution reaches peak concentrations in about an hour; elimination half-life is roughly 7–8 hours. Prolonged-release capsules modify absorption, not the underlying molecule. Liver or kidney impairment can increase exposure.

How do treatment options differ?

NICE lists galantamine, donepezil and rivastigmine as Alzheimer treatment options. Differences in administration, interactions and tolerability can matter more than brand familiarity. This is guidance for clinical decisions, not proof of identical funding or referral arrangements throughout the UK.

A closer look at the science

It is a tertiary alkaloid and a reversible, competitive acetylcholinesterase inhibitor. The product information also describes enhancement of nicotinic acetylcholine-receptor activity, probably through an allosteric site. A laboratory mechanism is not evidence that it outperforms another medicine for a particular person.

How was this medicine developed?

The checked Gatalin XL record gives first authorisation in June 2015; the SyriMed solution dates from October 2016. These describe particular products, not the origin of galantamine as a substance. A newer product date does not establish a superior therapeutic effect.

Sources and References

  1. Gatalin XL 8 mg prolonged-release capsules: SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom; national/local prescribing arrangements vary.

  2. Galantamine 4 mg/ml oral solution: SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom; national/local prescribing arrangements vary.

  3. Gatalin XL 8 mg, 16 mg and 24 mg capsules: patient leaflet

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom; national/local prescribing arrangements vary.

  4. Acetylcholinesterase inhibitors monitoring

    Scope: United Kingdom; national/local prescribing arrangements vary.

  5. NICE NG97: Dementia recommendations

    Scope: United Kingdom; national/local prescribing arrangements vary.

  6. NICE TA217: What has NICE said?

    Scope: United Kingdom; national/local prescribing arrangements vary.

  7. Drugs for dementia: galantamine, information for primary care

    Scope: England — Greater Manchester local guidance.

  8. Galantamine immediate-release tablets: prescribing information — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: 12.1 Mechanism of Action; 12.3 Pharmacokinetics. This does not establish UK product authorisation or prescribing..

  9. Galantamine hydrobromide extended-release capsules: prescribing information — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: 12.1 Mechanism of Action; 12.3 Pharmacokinetics. This does not establish UK product authorisation or prescribing..

  10. Zunveyl (benzgalantamine): prescribing information — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: 12.1 Mechanism of Action; 12.3 Pharmacokinetics. This does not establish UK product authorisation or prescribing..

  11. Galantamine: MedlinePlus Drug Information — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: Why is this medication prescribed?; How should this medicine be used?. This does not establish UK product authorisation or prescribing..

  12. Schizophrenia
  13. NIMH: Understanding psychosis

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top